Loading...

PODCAST

Data in Biotech

Data in Biotech is a fortnightly podcast exploring how companies leverage data to drive innovation in life sciences. Every two weeks, Ross Katz, Principal and Data Science Lead at CorrDyn, sits down with an expert from the world of biotechnology to understand how they use data science to solve technical challenges, streamline operations, and further innovation in their business. You can learn more about CorrDyn - an enterprise data specialist that enables excellent companies to make smarter

science life sciences

All Episodes

01:13:04

How Standardized Cell Labeling Could Fix Biotech's...

Data in Biotech ·

2026/09/30

Flow cytometry can find a cell population in seconds, but naming it consistently across labs is a problem still unsolved.If you've ever tried to compare cytometry data across studies, CROs, or even two scientists in the same lab, you know the frustration: everyone gates their own way, and the same cell population ends up with three different definitions. That inconsistency is quietly limiting what AI can do with biotech data. Ryan Brinkman is VP Research Director of Flow Cytometry

en

00:52:12

DrugBank CEO: Why Your AI Model Is Only Giving You...

Data in Biotech ·

2026/09/17

Ask a general AI model how many approved drugs hit a target, and it might tell you three when the real answer is six, sounding just as confident either way.If your team is grounding drug discovery decisions in AI output with no way to trace where the answer came from, you're one regulator's question away from a very expensive problem. Lisa Downey is CEO of DrugBank, a structured biomedical intelligence platform cited in more than 60,000 papers and used by nine of the top 20 global pharma

en

01:10:08

How to Identify the Blind Spots in Your Biotech's...

Data in Biotech ·

2026/09/02

Most drug discovery genomic data comes from a thin slice of the world, and that bias follows every decision downstream.Your team can run a Mendelian randomization study on 35,000 patients and still walk away with a single signal that doesn't even apply to the population you care about. If your phenotype definitions are fuzzy, more data won't save you. Erika Kvikstad is a computational biologist who led precision medicine for cardiovascular disease at Bristol-Myers Squibb, working on

en

00:54:12

How to Turn Single-Cell Data Into a New Class of...

Data in Biotech ·

2026/08/19

Why treating the cell, not the protein, could turn chronic disease treatment into something closer to a cure.You've built single-cell pipelines that spit out clusters, p-values and target lists, but nothing that survives contact with the clinic. What if the clustering method itself is quietly leading you astray? Adam Freund is Founder and CEO of Arda Therapeutics, a biotech using single-cell sequencing to find the pathogenic cells driving chronic disease. He spent seven years as a Principal

en

01:02:56

Why Biotech Talks About AI But Won't Pay for the Data...

Data in Biotech ·

2026/08/05

Everyone in biotech agrees AI needs more data. Almost no one is willing to pay for it.If you're trying to build or buy a biotech AI model, you've hit the same wall: predictive performance depends on data your budget doesn't cover, and nobody in the field seems willing to close that gap. John Androsavich runs Ginkgo Datapoints, the bio AI data arm of Ginkgo Bioworks. He trained as an RNA scientist, spent years on the pharma side deciding which technologies were worth buying, and now sells the

en

00:58:07

Beyond Language: Why Drug Discovery Needs Physical...

Data in Biotech ·

2026/07/20

In this episode of Data in Biotech, host Ross Katz sits down with Woody Sherman, Founder and Chief Innovation Officer at PsiThera, for a conversation on why AI can transform drug discovery's paperwork and code while barely touching the hardest part of the problem: the molecules themselves. Woody's career runs through physical chemistry at MIT; over a decade at Schrödinger building tools the industry still relies on; founding Silicon Therapeutics (where his team took a small molecule STING

en

00:59:29

Synthesizable by Design: Rethinking AI's Role in...

Data in Biotech ·

2026/06/17

In this episode of Data in Biotech, host Ross Katz sits down with Paul Finn, Chief Scientific Officer at Oxford Drug Design, for a conversation on what it actually takes to find a drug molecule that works not just on paper but also in the lab, in the cell, and, ultimately, in the clinic. Paul brings four decades of experience across what became GSK, Pfizer, and a series of Oxford-area spinouts and has shepherded a compound all the way to a marketed drug. That perspective gives him a particular

en

00:46:54

From Tissue to Mechanism to Decision: Building AI for...

Data in Biotech ·

2026/06/02

In this episode of Data in Biotech, host Ross Katz sits down with Arvind Rao, Professor of Computational Medicine and Bioinformatics at the University of Michigan, for a discussion on the gap between what biomedical AI can do and what it can reliably be trusted to do in clinical practice. Arvind's research sits at the intersection of computational oncology and AI governance and his lab works across H&E histopathology, multiplex immunofluorescence, spatial transcriptomics, and single-cell

en

00:58:42

Cavities in the Data: Building FDA-Cleared AI for...

Data in Biotech ·

2026/05/13

In this episode of Data in Biotech, host Ross Katz sits down with Sadegh Salehi, Director of Research and Principal Scientist at Overjet, to explore what rigorous model evaluation actually looks like when the stakes are clinical. Overjet builds FDA-cleared vision models that detect and quantify dental disease across billions of X-ray images from thousands of practices - a data problem with a staggering number of dimensions. Thirty-two teeth per adult patient, each with different morphology

en

00:42:52

Data as a Moat: Why Biotech's Most Valuable Asset is...

Data in Biotech ·

2026/04/30

In this episode of Data in Biotech, host Ross Katz sits down with Jesse Johnson, founder of Merelogic, a software consulting firm specializing in data infrastructure for biotech organizations. Jesse brings a rare perspective to the conversation: having built data systems at Google where engineers control the data collection function end to end, before moving into biotech, where the biology does what it wants and bench scientists, not engineers, generate the data. The result is a grounded,

en

00:49:54

The Patient is Not a Document: Foundation Models for...

Data in Biotech ·

2026/04/15

In this episode of Data in Biotech, host Ross Katz sits down with Kevin Brown, co-founder of Standard BioModel, to explore one of the most ambitious projects in biomedical AI, building a multimodal foundation model that represents the full complexity of a patient across time. Drawing on a career spanning brain-computer interfaces, computer-aided diagnosis at Siemens Healthineers, and oncology data science at Bristol Myers Squibb, Kevin shares the scientific and philosophical journey that led

en

00:57:31

Physics, Free Energy, & Drug Discovery: Inside...

Data in Biotech ·

2026/04/01

In this episode of Data in Biotech, Ross Katz sits down with Robert Abel, Chief Scientific Officer of the Platform at Schrödinger, to explore how physics-based computational modeling is transforming drug discovery. Robert unpacks why machine learning alone isn't enough to navigate the vast complexity of chemical space - an estimated at 10⁶⁰ possible drug-like molecules - and how integrating atomistic simulations with ML creates a more accurate, reliable, and scalable approach to identifying

en

00:30:29

AI in biotech: separating hype from reality with Ben...

Data in Biotech ·

2026/03/11

In this episode of Data in Biotech, host Ross Katz sits down with Ben Locwin, Vice President at Reliant Life Sciences, to explore the evolving landscape of artificial intelligence in biotechnology. Join us as we discuss why nearly every biotech claims to use AI but few actually do, examine successful applications like AlphaFold, and explore the challenges of implementing AI across drug development, manufacturing, and regulatory processes. Ben shares insights on maintaining healthy skepticism,

en

00:49:01

3D Printing Therapeutics at Scale with Aprecia...

Data in Biotech ·

2026/02/25

In this episode of Data in Biotech, Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine.What you'll learn in this

en

00:53:37

Success-Driven Drug Discovery with OpenBench CEO...

Data in Biotech ·

2026/02/11

In this episode of Data in Biotech, host Ross Katz sits down with James Yoder, Founder and CEO of OpenBench, to unpack a radical new approach to early-stage drug discovery. James shares how OpenBench's "success-driven" model shifts risk away from biotech partners by only charging for validated hits. They dive deep into computational screening, molecular modeling, and the company's evolving tech stack that's making hit discovery smarter and more accessible. Discover how data, AI, and strategic

en

00:52:33

Brant Peterson on Valo Health’s patient-first...

Data in Biotech ·

2026/01/29

Brant Peterson, Vice President & Fellow at Valo Health, joins Data in Biotech to explore how his team leverages real-world data, genetic insights, and machine learning to de-risk drug discovery. From building causal DAGs to identifying patient subtypes in neurodegenerative diseases like Parkinson’s, this episode dives deep into a patient-first, data-driven approach to biomedical innovation.What You'll Learn in This Episode: >> How Valo Health uses real-world evidence and EHR data

en

00:43:22

Inside Dash Bio’s productized CRO model with Ander...

Data in Biotech ·

2026/01/14

Ander Tallet, co-founder and COO of Dash Bio and CEO of DigitalRadius, joins Ross Katz to discuss transforming the traditional CRO model through automation, transparency, and productization. Drawing on deep experience from Moderna, Science Exchange, and his leadership roles in digital transformation, Ander shares how Dash Bio is slashing turnaround times, improving data quality, and simplifying procurement for biotech companies. This episode unpacks the future of CRO services, strategic

en

00:46:31

From discovery to delivery: AI’s impact on nanomedicine

Data in Biotech ·

2025/12/31

In this episode of Data in Biotech, Ross Katz chats with Mitra Mosharraf, Chief Scientific Officer at HTD Biosystems, about how AI and machine learning are revolutionizing nanomedicine. They explore the use of AI in drug discovery, formulation, manufacturing, and clinical development, highlighting how data-driven strategies are improving safety, reducing costs, and enabling more personalized therapies in the biotech space.What you'll learn in this episode: >> How AI and ML reduce costs

en

00:45:24

Jaidev Chakka on building the future of bioprinted...

Data in Biotech ·

2025/12/26

In this episode of Data in Biotech, Ross Katz chats with Jaidev Chakka, Principal Scientist at the University of Mississippi School of Pharmacy, about how 3D bioprinting and AI are reshaping pharmaceutical manufacturing. They explore the development of custom scaffolds for tissue engineering, the integration of gene delivery systems, and how data-driven approaches are enabling smarter, more scalable solutions in personalized medicine.What you'll learn in this episode: >> How 3D

en

00:25:34

From screening to IND: How Veloxity accelerates...

Data in Biotech ·

2025/12/22

In this episode of Data in Biotech, Ross Katz sits down with Callie Celichowski and Isa Kupke from Veloxity Labs to discuss how their CRO leverages speed, precision, and innovation to support drug development. Learn how they use mass spectrometry, cloud-based infrastructure, and hands-on client partnerships to drive rapid, high-quality bioanalytical insights that support everything from preclinical studies to FDA submissions. What you'll learn in this episode: >> Why "speed with

en

79 results

Similar Podcasts

Beyond the Divide

Koala Moon

The SCP Experience

Dr. NoSleep Studios

John Michael Godier"s Event Horizon

John Michael Godier

La Science CQFD

France Culture

A Moment of Science

Indiana Public Media